Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis

被引：0
|
作者：
Pham, Dung [1 ]
St-Onge, Louise [1 ]
Ng, Ryan [2 ]
Neish, Calum S. [2 ]
Yap, Belinda [3 ]
Apple, Stephen [4 ]
机构：
[1] Mitsubishi Tanabe Pharma Canada Inc, Toronto, ON, Canada
[2] IQVIA Solut Canada Inc, Toronto, ON, Canada
[3] Innomar Strategies, Oakville, ON, Canada
[4] Mitsubishi Tanabe Pharma Amer, Jersey City, NJ USA
来源：
MUSCLE & NERVE | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
89
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [31] Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
    Rosenbach, Kevin
    Park, Michelle
    Sanchirico, Marie
    Nwose, Oliseyenum
    Paris, Kenneth
    JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (05) : 912 - 920
  • [32] A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis
    Shefner, Jeremy M.
    Watson, Mary Lou
    Meng, Lisa
    Wolff, Andrew A.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (7-8) : 574 - 581
  • [33] Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
    Kevin Rosenbach
    Michelle Park
    Marie Sanchirico
    Oliseyenum Nwose
    Kenneth Paris
    Journal of Clinical Immunology, 2023, 43 (5) : 912 - 920
  • [34] Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
    Park, Jin-Mo
    Kim, Sun-Young
    Park, Donghwi
    Park, Jin-Sung
    NEUROLOGICAL SCIENCES, 2020, 41 (01) : 119 - 123
  • [35] Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
    Jin-Mo Park
    Sun-Young Kim
    Donghwi Park
    Jin-Sung Park
    Neurological Sciences, 2020, 41 : 119 - 123
  • [36] Safety, Tolerability, and Cerebrospinal Fluid Penetration of Ursodeoxycholic Acid in Patients With Amyotrophic Lateral Sclerosis
    Parry, Gareth J.
    Rodrigues, Cecilia M. P.
    Aranha, Marcia M.
    Hilbert, Sarah J.
    Davey, Cynthia
    Kelkar, Praful
    Low, Walter C.
    Steer, Clifford J.
    CLINICAL NEUROPHARMACOLOGY, 2010, 33 (01) : 17 - 21
  • [37] Edaravone for amyotrophic lateral sclerosis: More evidence for long-term benefit
    Distad, B. Jane
    Weiss, Michael D.
    MUSCLE & NERVE, 2020, 61 (02) : 129 - 130
  • [38] Efficacy, tolerability and safety of teriflunomide in multiple sclerosis in a real-world clinical setting
    Oreja-Guevara, C.
    Orviz-Garcia, A.
    Guerra-Schulz, E.
    Lopez de Velasco, V.
    Lopez-Perez, F.
    Palacios, M.
    Gonzalez-Suarez, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 544 - 544
  • [39] Baseline characteristics of patients from ongoing post-marketing surveillance, evaluating the real-world efficacy and safety of edaravone, a novel, free radical scavenger, for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan)
    Yuki, Satoshi
    Ishizaki, Kaoru
    Yoshioka, Hanami
    Nakamura, Hidekazu
    Hirai, Manabu
    Sobue, Gen
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2020, 8 (05): : 261 - 269
  • [40] Safety of butylphthalide and edaravone in patients with ischemic stroke: a multicenter real-world study
    Lyu, Shu-Xian
    Qian, Dong-Fang
    Feng, Yu-Fei
    Shen, Cheng-Wu
    Guo, Lu-Bo
    Lyu, Jian-Tao
    Jin, Peng-Fei
    Li, Ting
    Tan, Si-Yuan
    Zhang, Zi-Xuan
    Huang, Lin
    Zhong, Xue
    Su, Le-Qun
    Hu, Xin
    Huang, Xin
    Cui, Xue-Yan
    JOURNAL OF GERIATRIC CARDIOLOGY, 2023, 20 (04) : 293 - 308
12345